Since June 2015, Francois Martelet, MD, MBA is the CEO of NetScientific plc, a transatlantic London based healthcare IP commercialisation group focused on Diagnostics, Digital Health and Therapeutics. Until June 2014, Francois was Interim SVP, International Operations at Stallergenes SA, heading up its International Operations in the field of allergy therapeutics. He was previously CEO at Topotarget A/S, a publicly traded European biotech company specialized in oncology therapeutics succesefully merged with BioAlliance SA. He is a Pharmaceutical Executive with over 20 years of US and international experience at both corporate and operational level in blue chip pharma Cos. He brings senior level experience in clinical development, business development, licensing in and M&A, marketing, and sales experiences. His areas of expertise at general management level include mid/late stage development and commercialization of oncology products and managing large P&L ($1+B) across large country organizations in senior level regional roles with full accountability of multiple product lines in primary care and specialty markets in Europe and Emerging markets. He introduced over 12 products in oncology to many markets across the world, and more than six of them have become worldwide blockbusters. He served as CEO of Avax Tech Inc., a US biotech company specialized in therapeutic oncology vaccines. Francois worked for Novartis Pharma AG as SVP and Region Head Europe, Vice President InterContinental Region Head-Oncology Division and Vice President & Global Oncology Franchise Head at Merck and Co., Inc. He is also Trade Advisor at Ministry of Foreign Trade, France since January 2011. He is also a Board Member at the European BioPharmaceutical Enterprises (EFPIA division) since June 2012.